EGFR and non-small cell lung carcinoma: Key examples of antibody constructs targeting kinases include Trastuzumab and T-DM1 (targeting ERBB2/HER2) in breast and bladder cancer [175, 176], Bevacizumab (targeting VEGF) in ovarian, metastatic colon cancer and glioblastoma [177], Cetuximab, Panitumumab and necitumumab (targeting EGFR) in colorectal cancer and NSCLC [178].